Trial Profile
Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of abacavir/lamivudine/dolutegravir CNS-Related Neurotoxicity After Switching to tenofovir alafenamide/emtricitabine/darunavir/cobicistat
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms DETOX
- 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 06 Aug 2020 Status changed from recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 15 Dec 2019 to 15 May 2020.